Clinical relevance of cyclic GMP modulators: A translational success story of network pharmacology

Therapies that modulate cyclic guanosine‐3′‐5′‐monophosphate (cGMP) have emerged as one of the most successful areas in recent drug discovery and clinical pharmacology. Historically, their focus has been on cardiovascular disease phenotypes; however, cGMP's relevance is likely to go beyond this...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology and therapeutics 2016-04, Vol.99 (4), p.360-362
Main Authors: Oettrich, JM, Dao, VT, Frijhoff, J, Kleikers, PWM, Casas, AI, Hobbs, AJ, Schmidt, HHHW
Format: Article
Language:English
Subjects:
Animals
Biomarkers, Pharmacological - metabolism
Cyclic GMP - metabolism
Drug Discovery - methods
Enzyme Activation
Enzyme Activators - chemistry
Enzyme Activators - pharmacology
Guanylate Cyclase - metabolism
Humans
Molecular Structure
Phosphodiesterase Inhibitors - chemistry
Phosphodiesterase Inhibitors - pharmacology
Receptors, Guanylate Cyclase-Coupled - agonists
Receptors, Guanylate Cyclase-Coupled - metabolism
Second Messenger Systems - drug effects
Structure-Activity Relationship
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3886-234fc2634cd89bf9b4fb68dcfbe89b3a1ec133f96c4197096890f02d957f65df3
cites cdi_FETCH-LOGICAL-c3886-234fc2634cd89bf9b4fb68dcfbe89b3a1ec133f96c4197096890f02d957f65df3
container_end_page 362
container_issue 4
container_start_page 360
container_title Clinical pharmacology and therapeutics
container_volume 99
creator Oettrich, JM
Dao, VT
Frijhoff, J
Kleikers, PWM
Casas, AI
Hobbs, AJ
Schmidt, HHHW
description Therapies that modulate cyclic guanosine‐3′‐5′‐monophosphate (cGMP) have emerged as one of the most successful areas in recent drug discovery and clinical pharmacology. Historically, their focus has been on cardiovascular disease phenotypes; however, cGMP's relevance is likely to go beyond this rather limited organ‐based set of indications. Moreover, the multitude of targets and their apparent interchangeability is a proof‐of‐concept of network pharmacology.
doi_str_mv 10.1002/cpt.336
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1772837079</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1772837079</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3886-234fc2634cd89bf9b4fb68dcfbe89b3a1ec133f96c4197096890f02d957f65df3</originalsourceid><addsrcrecordid>eNp1kMFu1DAURS1URIeC-geVd62EMjh2YsfdjUYwBYahiyKqbiznxYa0Tjy1E0r-Hlcp3bF6unrnnsVF6Dgny5wQ-h72w5Ix_gIt8pLRjJesPEALQojMJGX8EL2O8TbFQlbVK3RIueAlpXSB6rVr-xa0w8E481v3YLC3GCZwLeDN10vc-WZ0evAhnuMVHoLuY4qt71MnjgAmRhzTe3rs9WZ48OEO73_p0Gnwzv-c3qCXVrto3j7dI_T944er9UW2_bb5tF5tM2BVxTPKCguUswKaStZW1oWtedWArU3KTOcGcsas5FDkUhDJK0ksoY0sheVlY9kROpu9--DvRxMH1bURjHO6N36MKheCVkwQIRN6OqMQfIzBWLUPbafDpHKiHgdVaVCVBk3kyZN0rDvTPHP_FkzAuxl4aJ2Z_udR68urWZfNdBsH8-eZ1uFOccFEqX7sNupi92VzveU36jP7CzAojwU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1772837079</pqid></control><display><type>article</type><title>Clinical relevance of cyclic GMP modulators: A translational success story of network pharmacology</title><source>Wiley</source><creator>Oettrich, JM ; Dao, VT ; Frijhoff, J ; Kleikers, PWM ; Casas, AI ; Hobbs, AJ ; Schmidt, HHHW</creator><creatorcontrib>Oettrich, JM ; Dao, VT ; Frijhoff, J ; Kleikers, PWM ; Casas, AI ; Hobbs, AJ ; Schmidt, HHHW</creatorcontrib><description>Therapies that modulate cyclic guanosine‐3′‐5′‐monophosphate (cGMP) have emerged as one of the most successful areas in recent drug discovery and clinical pharmacology. Historically, their focus has been on cardiovascular disease phenotypes; however, cGMP's relevance is likely to go beyond this rather limited organ‐based set of indications. Moreover, the multitude of targets and their apparent interchangeability is a proof‐of‐concept of network pharmacology.</description><identifier>ISSN: 0009-9236</identifier><identifier>EISSN: 1532-6535</identifier><identifier>DOI: 10.1002/cpt.336</identifier><identifier>PMID: 26765222</identifier><language>eng</language><publisher>United States: Blackwell Publishing Ltd</publisher><subject>Animals ; Biomarkers, Pharmacological - metabolism ; Cyclic GMP - metabolism ; Drug Discovery - methods ; Enzyme Activation ; Enzyme Activators - chemistry ; Enzyme Activators - pharmacology ; Guanylate Cyclase - metabolism ; Humans ; Molecular Structure ; Phosphodiesterase Inhibitors - chemistry ; Phosphodiesterase Inhibitors - pharmacology ; Receptors, Guanylate Cyclase-Coupled - agonists ; Receptors, Guanylate Cyclase-Coupled - metabolism ; Second Messenger Systems - drug effects ; Structure-Activity Relationship</subject><ispartof>Clinical pharmacology and therapeutics, 2016-04, Vol.99 (4), p.360-362</ispartof><rights>2016 American Society for Clinical Pharmacology and Therapeutics</rights><rights>2016 American Society for Clinical Pharmacology and Therapeutics.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3886-234fc2634cd89bf9b4fb68dcfbe89b3a1ec133f96c4197096890f02d957f65df3</citedby><cites>FETCH-LOGICAL-c3886-234fc2634cd89bf9b4fb68dcfbe89b3a1ec133f96c4197096890f02d957f65df3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27911,27912</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26765222$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Oettrich, JM</creatorcontrib><creatorcontrib>Dao, VT</creatorcontrib><creatorcontrib>Frijhoff, J</creatorcontrib><creatorcontrib>Kleikers, PWM</creatorcontrib><creatorcontrib>Casas, AI</creatorcontrib><creatorcontrib>Hobbs, AJ</creatorcontrib><creatorcontrib>Schmidt, HHHW</creatorcontrib><title>Clinical relevance of cyclic GMP modulators: A translational success story of network pharmacology</title><title>Clinical pharmacology and therapeutics</title><addtitle>Clin. Pharmacol. Ther</addtitle><description>Therapies that modulate cyclic guanosine‐3′‐5′‐monophosphate (cGMP) have emerged as one of the most successful areas in recent drug discovery and clinical pharmacology. Historically, their focus has been on cardiovascular disease phenotypes; however, cGMP's relevance is likely to go beyond this rather limited organ‐based set of indications. Moreover, the multitude of targets and their apparent interchangeability is a proof‐of‐concept of network pharmacology.</description><subject>Animals</subject><subject>Biomarkers, Pharmacological - metabolism</subject><subject>Cyclic GMP - metabolism</subject><subject>Drug Discovery - methods</subject><subject>Enzyme Activation</subject><subject>Enzyme Activators - chemistry</subject><subject>Enzyme Activators - pharmacology</subject><subject>Guanylate Cyclase - metabolism</subject><subject>Humans</subject><subject>Molecular Structure</subject><subject>Phosphodiesterase Inhibitors - chemistry</subject><subject>Phosphodiesterase Inhibitors - pharmacology</subject><subject>Receptors, Guanylate Cyclase-Coupled - agonists</subject><subject>Receptors, Guanylate Cyclase-Coupled - metabolism</subject><subject>Second Messenger Systems - drug effects</subject><subject>Structure-Activity Relationship</subject><issn>0009-9236</issn><issn>1532-6535</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNp1kMFu1DAURS1URIeC-geVd62EMjh2YsfdjUYwBYahiyKqbiznxYa0Tjy1E0r-Hlcp3bF6unrnnsVF6Dgny5wQ-h72w5Ix_gIt8pLRjJesPEALQojMJGX8EL2O8TbFQlbVK3RIueAlpXSB6rVr-xa0w8E481v3YLC3GCZwLeDN10vc-WZ0evAhnuMVHoLuY4qt71MnjgAmRhzTe3rs9WZ48OEO73_p0Gnwzv-c3qCXVrto3j7dI_T944er9UW2_bb5tF5tM2BVxTPKCguUswKaStZW1oWtedWArU3KTOcGcsas5FDkUhDJK0ksoY0sheVlY9kROpu9--DvRxMH1bURjHO6N36MKheCVkwQIRN6OqMQfIzBWLUPbafDpHKiHgdVaVCVBk3kyZN0rDvTPHP_FkzAuxl4aJ2Z_udR68urWZfNdBsH8-eZ1uFOccFEqX7sNupi92VzveU36jP7CzAojwU</recordid><startdate>201604</startdate><enddate>201604</enddate><creator>Oettrich, JM</creator><creator>Dao, VT</creator><creator>Frijhoff, J</creator><creator>Kleikers, PWM</creator><creator>Casas, AI</creator><creator>Hobbs, AJ</creator><creator>Schmidt, HHHW</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201604</creationdate><title>Clinical relevance of cyclic GMP modulators: A translational success story of network pharmacology</title><author>Oettrich, JM ; Dao, VT ; Frijhoff, J ; Kleikers, PWM ; Casas, AI ; Hobbs, AJ ; Schmidt, HHHW</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3886-234fc2634cd89bf9b4fb68dcfbe89b3a1ec133f96c4197096890f02d957f65df3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Animals</topic><topic>Biomarkers, Pharmacological - metabolism</topic><topic>Cyclic GMP - metabolism</topic><topic>Drug Discovery - methods</topic><topic>Enzyme Activation</topic><topic>Enzyme Activators - chemistry</topic><topic>Enzyme Activators - pharmacology</topic><topic>Guanylate Cyclase - metabolism</topic><topic>Humans</topic><topic>Molecular Structure</topic><topic>Phosphodiesterase Inhibitors - chemistry</topic><topic>Phosphodiesterase Inhibitors - pharmacology</topic><topic>Receptors, Guanylate Cyclase-Coupled - agonists</topic><topic>Receptors, Guanylate Cyclase-Coupled - metabolism</topic><topic>Second Messenger Systems - drug effects</topic><topic>Structure-Activity Relationship</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Oettrich, JM</creatorcontrib><creatorcontrib>Dao, VT</creatorcontrib><creatorcontrib>Frijhoff, J</creatorcontrib><creatorcontrib>Kleikers, PWM</creatorcontrib><creatorcontrib>Casas, AI</creatorcontrib><creatorcontrib>Hobbs, AJ</creatorcontrib><creatorcontrib>Schmidt, HHHW</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical pharmacology and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Oettrich, JM</au><au>Dao, VT</au><au>Frijhoff, J</au><au>Kleikers, PWM</au><au>Casas, AI</au><au>Hobbs, AJ</au><au>Schmidt, HHHW</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical relevance of cyclic GMP modulators: A translational success story of network pharmacology</atitle><jtitle>Clinical pharmacology and therapeutics</jtitle><addtitle>Clin. Pharmacol. Ther</addtitle><date>2016-04</date><risdate>2016</risdate><volume>99</volume><issue>4</issue><spage>360</spage><epage>362</epage><pages>360-362</pages><issn>0009-9236</issn><eissn>1532-6535</eissn><abstract>Therapies that modulate cyclic guanosine‐3′‐5′‐monophosphate (cGMP) have emerged as one of the most successful areas in recent drug discovery and clinical pharmacology. Historically, their focus has been on cardiovascular disease phenotypes; however, cGMP's relevance is likely to go beyond this rather limited organ‐based set of indications. Moreover, the multitude of targets and their apparent interchangeability is a proof‐of‐concept of network pharmacology.</abstract><cop>United States</cop><pub>Blackwell Publishing Ltd</pub><pmid>26765222</pmid><doi>10.1002/cpt.336</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0009-9236
ispartof Clinical pharmacology and therapeutics, 2016-04, Vol.99 (4), p.360-362
issn 0009-9236
1532-6535
language eng
recordid cdi_proquest_miscellaneous_1772837079
source Wiley
subjects Animals
Biomarkers, Pharmacological - metabolism
Cyclic GMP - metabolism
Drug Discovery - methods
Enzyme Activation
Enzyme Activators - chemistry
Enzyme Activators - pharmacology
Guanylate Cyclase - metabolism
Humans
Molecular Structure
Phosphodiesterase Inhibitors - chemistry
Phosphodiesterase Inhibitors - pharmacology
Receptors, Guanylate Cyclase-Coupled - agonists
Receptors, Guanylate Cyclase-Coupled - metabolism
Second Messenger Systems - drug effects
Structure-Activity Relationship
title Clinical relevance of cyclic GMP modulators: A translational success story of network pharmacology
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T13%3A29%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20relevance%20of%20cyclic%20GMP%20modulators:%20A%20translational%20success%20story%20of%20network%20pharmacology&rft.jtitle=Clinical%20pharmacology%20and%20therapeutics&rft.au=Oettrich,%20JM&rft.date=2016-04&rft.volume=99&rft.issue=4&rft.spage=360&rft.epage=362&rft.pages=360-362&rft.issn=0009-9236&rft.eissn=1532-6535&rft_id=info:doi/10.1002/cpt.336&rft_dat=%3Cproquest_cross%3E1772837079%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3886-234fc2634cd89bf9b4fb68dcfbe89b3a1ec133f96c4197096890f02d957f65df3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1772837079&rft_id=info:pmid/26765222&rfr_iscdi=true